{"id":"W2465799764","doi":"10.1111/bjd.14871","title":"Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial","year":2016,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research; Innovaderm (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Eczema Area and Severity Index; Tolerability; Medicine; Janus kinase inhibitor; Atopic dermatitis; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Pharmacodynamics; Dermatology; Pharmacokinetics; Onset of action; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001995818,0.001224238,0.002070701,0.0004061052,0.000349696,0.001183947,0.0006479566,0.001722978,0.0115223],"category_scores_gemma":[0.001079847,0.0004505575,0.001956711,0.0004682016,0.0005729167,0.0006960658,0.0002441411,0.001948741,0.001275259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006173006,"about_ca_system_score_gemma":0.001307812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006380323,"about_ca_topic_score_gemma":0.001519006,"domain_scores_codex":[0.9994732,0.0002661588,0.0000408491,0.00008415314,0.00005980923,0.00007585063],"domain_scores_gemma":[0.9993262,0.0001626679,0.0001864492,0.00005011919,0.00007208358,0.0002025161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.939725,0.006779573,0.0008731497,0.002619543,0.001875185,0.00008589673,0.00003416224,0.0003446767,0.006634839,0.0002293813,0.003629711,0.03716896],"study_design_scores_gemma":[0.9706862,0.02643268,0.0008645568,0.00007756732,0.0003947593,0.00003850132,0.000006549672,0.0001441069,0.0001954797,0.00007787566,0.001076219,0.000005505135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9032691,0.04618652,0.002046742,0.003345067,0.002130769,0.02440687,0.00581558,0.0004840982,0.01231533],"genre_scores_gemma":[0.9377566,0.02185136,0.003915973,0.005099938,0.001976521,0.01699287,0.004003266,0.00005489618,0.008348553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0115223,"threshold_uncertainty_score":0.03854591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01635605518526289,"score_gpt":0.300221266251213,"score_spread":0.2838652110659501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}